Apr 7 2012
GenVec, Inc. (NASDAQ: GNVC) announced publication of research on GenVec's new vaccine vectors. These vectors circumvent neutralizing antibodies in order to generate the desired immunologic response. The paper has been published online in PloS ONE, and can be accessed at http://dx.plos.org/10.1371/journal.pone.0033920. The article titled "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses" is an example of GenVec's proprietary vaccine technology.
"This paper describes one of several new tools we are using to generate better vaccines," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research. "This approach alters key elements of the vector so that a good vaccine response is generated even if an individual was previously exposed to an adenovirus. This technology expands our genetic vaccine toolbox used to create superior vaccines."
BMI's influence on disease pathogenesis uncovered in new research